Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:
MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), locally advanced or metastatic breast cancer (“ABC”) with a PIK3CA mutation, following progression on or after treatment with at least one line of endocrine therapy.
Brandywine Managers LLC acquired a new stake in shares of Celcuity, Inc. (NASDAQ: CELC) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 6,621 shares of the company's stock, valued at approximately $693,000. Several other hedge funds have also
Celcuity Inc. remains a Buy as the REVTORPYK/gedatolisib FDA approval and rapid NCCN Category 1 inclusion de-risk clinical and commercial adoption. CELC's financials reflect a front-loaded commercial investment, with SG&A surging for launch, but a strengthened $754M cash position provides funding visibility into 2029. VIKTORIA-1 data show REVTORPYK delivers a step-change in efficacy and tolerability, supporting rapid physician adoption and a potential blockbuster franchise.
Celcuity Inc (NASDAQ:CELC) reported a narrower-than-expected loss for the second quarter on Thursday.
MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:
MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), locally advanced or metastatic breast cancer (“ABC”) with a PIK3CA mutation, following progression on or after treatment with at least one line of endocrine therapy.
Brandywine Managers LLC acquired a new stake in shares of Celcuity, Inc. (NASDAQ: CELC) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 6,621 shares of the company's stock, valued at approximately $693,000. Several other hedge funds have also
Celcuity Inc. remains a Buy as the REVTORPYK/gedatolisib FDA approval and rapid NCCN Category 1 inclusion de-risk clinical and commercial adoption. CELC's financials reflect a front-loaded commercial investment, with SG&A surging for launch, but a strengthened $754M cash position provides funding visibility into 2029. VIKTORIA-1 data show REVTORPYK delivers a step-change in efficacy and tolerability, supporting rapid physician adoption and a potential blockbuster franchise.
Celcuity Inc (NASDAQ:CELC) reported a narrower-than-expected loss for the second quarter on Thursday.
Celcuity Inc. (CELC) Q2 2026 Earnings Call Transcript
Celcuity NASDAQ: CELC said it remains on track to begin commercial shipments of REVTORPYK, its gedatolisib therapy for certain patients with advanced breast cancer, late in the third quarter of 2026 following its recent FDA approval.
MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced financial results for the second quarter ended June 30, 2026 and other recent business developments.
California State Teachers Retirement System lifted its holdings in Celcuity, Inc. (NASDAQ: CELC) by 91.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,580 shares of the company's stock after buying an additional 12,201 shares during the quarter. California State Teachers Retirement
NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Celcuity Inc. ("Celcuity" or the "Company") (NASDAQ: CELC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that it will release its financial results for the second quarter 2026 after the market closes on Thursday, August 13, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Daylight Time to discuss the results and provide a corporate update.
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Celcuity Inc. (“Celcuity” or the “Company”) (NASDAQ: CELC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Celcuity (CELC) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Celcuity and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.
The law firm of [url="]Kirby McInerney LLP[/url] reminds investors of its investigation on behalf of Celcuity Inc. (âCelcuityâ or the âCompanyâ) (NASDAQ
NEW YORK--(BUSINESS WIRE)---- $CELC #classaction--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Celcuity Inc. (“Celcuity” or the “Company”) (NASDAQ: CELC) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On July 14, 2026, Celcuity issued a press release announcing that it had secured U.S. Food and Drug Administrati.
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
LOS ANGELES--(BUSINESS WIRE)---- $CELC--CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law.
CELC Investigation: Kessler Topaz Meltzer and Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm PR N
RADNOR, Pa., July 31, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Celcuity Inc. (NASDAQ: CELC) on behalf of investors who purchased or acquired Celcuity Inc. securities and experienced significant financial losses.
NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Celcuity Inc. ("Celcuity" or the "Company") (NASDAQ: CELC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
REVTORPYK (gedatolisib) in combination with fulvestrant, with or without palbociclib, listed as a preferred Category 1 regimen for second-line or subsequent treatment for tumors without a PIK3CA mutation following progression on or after at least one line of endocrine therapy REVTORPYK (gedatolisib) in combination with fulvestrant, with or without palbociclib, listed as a preferred Category 1 regimen for second-line or subsequent treatment for tumors without a PIK3CA mutation following progression on or after at least one line of endocrine therapy
RADNOR, Pa., July 29, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Celcuity Inc. (NASDAQ: CELC) on behalf of investors who purchased or acquired Celcuity Inc. securities and experienced significant financial losses.
RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Celcuity Inc. (NASDAQ: CELC) on behalf of investors who purchased or acquired Celcuity Inc. securities and experienced significant financial losses. Celcuity Announces Unexpected Delayed Drug Launch On July 14, 2026, Celcuity Inc. issued a press release announcing that it had secured F.
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Celcuity Inc. (“Celcuity” or the “Company”) (NASDAQ: CELC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Celcuity Inc. ("Celcuity" or the "Company") (NASDAQ: CELC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Celcuity (CELC) To Contact Him Directly To Discuss Their Options
Celcuity slides 15% despite FDA approval of Revtorpyk as investors focus on a late Q3 2026 launch that delays commercial sales and near-term revenues.
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Celcuity Inc. (“Celcuity” or the “Company”) (NASDAQ: CELC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Celcuity Inc. (“Celcuity” or the “Company”) (Nasdaq: CELC). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.
Celcuity (NASDAQ: CELC) said the U.S. Food and Drug Administration has granted full approval to gedatolisib, now branded as REVTORPYK, for certain patients with advanced breast cancer, marking the company's transition to a commercial-stage business. Brian Sullivan, Celcuity's co-founder and chief executive officer, said on a conference call that REVTORPYK was approved in the United States
NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Celcuity Inc. ("Celcuity" or the "Company") (NASDAQ: CELC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Celcuity Inc. (CELC) Discusses FDA Approval of REVTORPYK for Advanced HR+/HER2- Breast Cancer and Commercial Launch Plans Transcript
Celcuity Inc. secured FDA approval for REVTORPYK, the first pan-PI3K, mTORC1/2 inhibitor for 2nd-line PIK3CA wild-type HR+/HER2- advanced breast cancer. I downgrade CELC from Strong Buy to Buy due to phase 3 mutant cohort data underperforming prior results and rising competitive threats from Relay Therapeutics. REVTORPYK demonstrated strong efficacy in both wild-type and mutant cohorts, but delayed commercial launch and potential for superior competitor data temper near-term enthusiasm.
Shares of Celcuity fell about 8% in premarket trading on Wednesday, as the delayed commercial launch of its newly approved breast cancer drug and treatment-tolerability concerns overshadowed the company's first U.S. approval.
Celcuity NASDAQ: CELC said the U.S. Food and Drug Administration has granted full approval to gedatolisib, now branded as REVTORPYK, for certain patients with advanced breast cancer, marking the company's transition to a commercial-stage business.
MINNEAPOLIS, July 14, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced that the U.S. Food and Drug Administration (“FDA”) approved REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. REVTORPYK is the only inhibitor of class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 to receive FDA approval.
Celcuity Inc. (CELC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
